Literature DB >> 22896851

The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.

Kavi P Patel1, Thomas W O'Brien, Sankarasubramon H Subramony, Jonathan Shuster, Peter W Stacpoole.   

Abstract

CONTEXT: Pyruvate dehydrogenase complex (PDC) deficiency is a genetic mitochondrial disorder commonly associated with lactic acidosis, progressive neurological and neuromuscular degeneration and, usually, death during childhood. There has been no recent comprehensive analysis of the natural history and clinical course of this disease.
OBJECTIVE: We reviewed 371 cases of PDC deficiency, published between 1970 and 2010, that involved defects in subunits E1α and E1β and components E1, E2, E3 and the E3 binding protein of the complex. DATA SOURCES AND EXTRACTION: English language peer-reviewed publications were identified, primarily by using PubMed and Google Scholar search engines.
RESULTS: Neurodevelopmental delay and hypotonia were the commonest clinical signs of PDC deficiency. Structural brain abnormalities frequently included ventriculomegaly, dysgenesis of the corpus callosum and neuroimaging findings typical of Leigh syndrome. Neither gender nor any clinical or neuroimaging feature differentiated the various biochemical etiologies of the disease. Patients who died were younger, presented clinically earlier and had higher blood lactate levels and lower residual enzyme activities than subjects who were still alive at the time of reporting. Survival bore no relationship to the underlying biochemical or genetic abnormality or to gender.
CONCLUSIONS: Although the clinical spectrum of PDC deficiency is broad, the dominant clinical phenotype includes presentation during the first year of life; neurological and neuromuscular degeneration; structural lesions revealed by neuroimaging; lactic acidosis and a blood lactate:pyruvate ratio ≤ 20.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896851      PMCID: PMC4003492          DOI: 10.1016/j.ymgme.2012.03.017

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  173 in total

1.  Clinical studies of a patient with pyruvate decarboxylase deficiency.

Authors:  J P Blass; A P Kark; W K Engel
Journal:  Arch Neurol       Date:  1971-11

2.  Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism.

Authors:  G E Duncan; L A Perkins; D W Theriaque; R E Neiberger; P W Stacpoole
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

3.  Absence of pyruvate decarboxylase activity in man: a cause of congenital lactic acidosis.

Authors:  D F Farrell; A F Clark; C R Scott; R P Wennberg
Journal:  Science       Date:  1975-03-21       Impact factor: 47.728

4.  Late-onset presentation of pyruvate dehydrogenase deficiency.

Authors:  George Mellick; Lee Price; Richard Boyle
Journal:  Mov Disord       Date:  2004-06       Impact factor: 10.338

5.  Pyruvate dehydrogenase E1alpha subunit deficiency in a female patient: evidence of antenatal origin of brain damage and possible etiology of infantile spasms.

Authors:  Naoko Wada; Toyojiro Matsuishi; Michiko Nonaka; Etsuo Naito; Makoto Yoshino
Journal:  Brain Dev       Date:  2004-01       Impact factor: 1.961

6.  Pyruvate dehydrogenase deficiency presenting as dystonia in childhood.

Authors:  R A Head; C G E L de Goede; R W N Newton; J H Walter; M A McShane; R M Brown; G K Brown
Journal:  Dev Med Child Neurol       Date:  2004-10       Impact factor: 5.449

7.  Mutations in the gene for the E1beta subunit: a novel cause of pyruvate dehydrogenase deficiency.

Authors:  Ruth M Brown; Rosemary A Head; Ivan I Boubriak; James V Leonard; Neil H Thomas; Garry K Brown
Journal:  Hum Genet       Date:  2004-05-11       Impact factor: 4.132

8.  Lactic acidosis and developmental delay due to deficiency of E3 binding protein (protein X) of the pyruvate dehydrogenase complex.

Authors:  D G Ramadan; R A Head; A Al-Tawari; Y Habeeb; M Zaki; F Al-Ruqum; G T N Besley; J E Wraith; R M Brown; G K Brown
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

9.  Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids.

Authors:  S Whitehouse; R H Cooper; P J Randle
Journal:  Biochem J       Date:  1974-09       Impact factor: 3.857

10.  A defect in pyruvate decarboxylase in a child with an intermittent movement disorder.

Authors:  J P Blass; J Avigan; B W Uhlendorf
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

View more
  56 in total

Review 1.  Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?

Authors:  Alessio Di Fonzo; Edoardo Monfrini; Roberto Erro
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

Review 2.  Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes.

Authors:  Timothy J Edwards; Elliott H Sherr; A James Barkovich; Linda J Richards
Journal:  Brain       Date:  2014-01-28       Impact factor: 13.501

Review 3.  The pyruvate dehydrogenase complexes: structure-based function and regulation.

Authors:  Mulchand S Patel; Natalia S Nemeria; William Furey; Frank Jordan
Journal:  J Biol Chem       Date:  2014-05-05       Impact factor: 5.157

4.  Enzymatic testing sensitivity, variability and practical diagnostic algorithm for pyruvate dehydrogenase complex (PDC) deficiency.

Authors:  Ha Kyung Shin; George Grahame; Shawn E McCandless; Douglas S Kerr; Jirair K Bedoyan
Journal:  Mol Genet Metab       Date:  2017-09-08       Impact factor: 4.797

5.  Folding and assembly defects of pyruvate dehydrogenase deficiency-related variants in the E1α subunit of the pyruvate dehydrogenase complex.

Authors:  Srdja Drakulic; Jay Rai; Steen Vang Petersen; Monika M Golas; Bjoern Sander
Journal:  Cell Mol Life Sci       Date:  2018-02-14       Impact factor: 9.261

6.  Ketone Bodies as a Possible Adjuvant to Ketogenic Diet in PDHc Deficiency but Not in GLUT1 Deficiency.

Authors:  F Habarou; N Bahi-Buisson; E Lebigot; C Pontoizeau; M T Abi-Warde; A Brassier; K H Le Quan Sang; C Broissand; S Vuillaumier-Barrot; A Roubertie; A Boutron; C Ottolenghi; P de Lonlay
Journal:  JIMD Rep       Date:  2017-05-17

7.  E4F1 controls a transcriptional program essential for pyruvate dehydrogenase activity.

Authors:  Matthieu Lacroix; Geneviève Rodier; Olivier Kirsh; Thibault Houles; Hélène Delpech; Berfin Seyran; Laurie Gayte; Francois Casas; Laurence Pessemesse; Maud Heuillet; Floriant Bellvert; Jean-Charles Portais; Charlene Berthet; Florence Bernex; Michele Brivet; Audrey Boutron; Laurent Le Cam; Claude Sardet
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

Review 8.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

9.  Arsenic exposure induces glucose intolerance and alters global energy metabolism.

Authors:  Andrew G Kirkley; Christopher M Carmean; Daniel Ruiz; Honggang Ye; Shane M Regnier; Ananta Poudel; Manami Hara; Wakanene Kamau; Daniel N Johnson; Austin A Roberts; Patrick J Parsons; Susumu Seino; Robert M Sargis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-14       Impact factor: 3.619

10.  mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.

Authors:  Simon C Johnson; Melana E Yanos; Ernst-Bernhard Kayser; Albert Quintana; Maya Sangesland; Anthony Castanza; Lauren Uhde; Jessica Hui; Valerie Z Wall; Arni Gagnidze; Kelly Oh; Brian M Wasko; Fresnida J Ramos; Richard D Palmiter; Peter S Rabinovitch; Philip G Morgan; Margaret M Sedensky; Matt Kaeberlein
Journal:  Science       Date:  2013-11-14       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.